Sep 12, 2020

Antiviral Drug Remdesivir Can Help Fight the Coronavirus, But Can Patients Get It?

Posted by in category: biotech/medical

An early analysis of the data, which did not include patients enrolled later in the trial, found that median time to recovery was 11 days for patients on remdesivir and 15 days for patients on placebo. It also suggested a lower death rate, 8 percent on remdesivir compared to 11.6 percent on placebo, but that difference was just short of statistical significance.

UCSF and Zuckerberg San Francisco General Hospital together enrolled about 30 patients in the NIH trial. Because the trial was double-blinded, neither the doctors nor the patients knew which patients received remdesivir or placebo. With survival rates in San Francisco relatively high compared to harder hit cities, it was hard to attribute any specific improvement to the drug, said Chin-Hong and Doernberg, who both cared for patients in the trial.

“We’re talking about a couple days of faster recovery overall, so in any one particular patient, that may not be so apparent,” said Doernberg. “This is why you have to do large trials.”

Leave a reply